亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Blockade of CD40-TRAF2 Interaction and IL-1 in Control of Inflammatory Disorders

詳細技術說明
As a pro-inflammatory molecule, CD40 and its ligand CD154 play a central role in the development and/or progression of a variety of diseases with an inflammatory component such as atherosclerosis, aut
*Abstract

As a pro-inflammatory molecule, CD40 and its ligand CD154 play a central role in the development and/or progression of a variety of diseases with an inflammatory component such as atherosclerosis, autoimmune disorders, Crohn's Disease, rejection of transplanted organs and stroke. Thus, the CD40-CD154 pathway has become an attractive therapeutic target for the treatment of a broad variety of human diseases. Clinical trials have been undertaken based on administration of a blocking anti-CD154 antibody for treatment of lupus nephritis, Crohn's disease and Immune Thrombocytopenic Purpura. While the anti-CD154 antibodies appeared clinically effective, some patients experienced heart attacks. This side effect was not caused by blockade of CD40 signaling but rather by an unexpected effect of the anti-CD154 antibody on platelets (platelet aggregation). Dr. Carlos Subauste has developed a different approach to block the effect of CD40 that should not cause platelet aggregation. Rather than employing an antibody-based approach to block CD40-CD154 signaling, Dr. Subauste has developed and identified through HTS agents that at low concentrations act intra-cellularly to block signals downstream of CD40 that drive inflammatory responses. The agents have been demonstrated to be highly effective in in vitro testing, and now, a proprietary in vivo model has also been developed to provide animal data.Recently, Dr. Subauste's lab has now tested an identified blocking peptide in vivo using mice. The peptide successfully inhibited inflammation. This has been done twice. The peptide also inhibits pro-inflammatory responses in vitro using human cells. Dr. Subauste also has continued with testing of the small molecules identified by their high throughput screening process. There is at least one compound that also inhibits inflammatory responses in human cells.

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備